Table 2.
GALNT14-rs9679162 SNP in different gastrointestinal (GI) cancers.
| Type of GI Cancer | Case Number and Treatment | Unfavorable Genotype (% of Total Patient) | Prognostic Value | Reference |
|---|---|---|---|---|
| Esophageal squamous cell carcinoma | 108 patients with advanced esophageal squamous cell carcinoma with CCRT | “GG” (26.1%) | 1. Lower rate of CCRT response (24.1% vs. 50.6%, p = 0.014) 2. Longer time to complete/partial response (HR 0.385, p = 0.022) |
[27] |
| Gastric signet ring cell carcinoma | 347 patients with gastric signet ring cell carcinoma receiving surgical resection | “TT” (23.3%) | 1. In advanced stage (IIB to IV) group, unfavorable OS (HR = 1.550, p = 0.048) 2. In N > 0 subgroup, unfavorable OS (HR 1.808, p = 0.0013) 3. In lymphatic invasion subgroup, unfavorable OS (HR 1.587, p = 0.0021) 4. In vascular invasion subgroup, unfavorable OS (HR 3.389, p = 0.0076) 5. In perineural invasion subgroup, unfavorable OS (HR 1.604, p = 0.0161) |
[29] |
| Colorectal adenocarcinoma | 300 patients with stage III colorectal cancer with oxaliplatin based adjuvant CT | “TT” (18.1%) | 1. Unfavorable OS (HR = 5.406, p = 0.019) 2. In age ≤ 65 y subgroup, unfavorable OS (HR = 5.051, p = 0.024) 3. In male subgroup, unfavorable OS (HR = 7.337, p = 0.030) 4. In left side colorectal cancer group, unfavorable OS (HR = 7.857, p = 0.026) 5. In N2 stage subgroup, unfavorable OS (HR = 6.017, p = 0.049) 6. In CEA > 5 ng/mL subgroup, unfavorable OS (HR = 11.295, p = 0.049) 7. In mucinous histology subgroup, unfavorable OS (HR = 13.296, p = 0.037) |
[33] |
| Pancreatic ductal adenocarcinoma | 103 patients with pancreatic adenocarcinoma receiving surgical resection | “Non-GG (TG + TT)”(80.6%) | 1. Lower mean OS time (16.1 vs. 37.1 months, p = 0.005) 2. Unfavorable OS (HR = 3.663, p = 0.003) |
[35] |
| Cholangiocarcinoma | 112 patients with cholangiocarcinoma receiving surgical resection | “TT” (31.3%) | 1. Unfavorable OS (HR = 2.282, p = 0.023) 2. Associated with perineural invasion (p = 0.035) 3. Associated with LN metastasis (p = 0.005) |
[37] |
Abbreviations: CCRT, concurrent chemoradiotherapy; HR, hazard ratio; OS, overall survival; CEA, carcinoembryonic antigen; LN, lymph node; C/T, chemotherapy; GALNT14, N-acetylgalactosaminyltransferase14.